Evidence map›Paper›PMID 41972188›Full record

ArticleFrontiers in immunology2026

Abrine targets ERK to suppress EMT and lung metastasis model via MAPKs and Nrf2/Keap-1/HO-1 signaling.

Yufang Shen, Linyu Xiao, Lina Liu, Lianting Liao, Xianmin Zou, Pengfei Shen, Jinlong Zhao, Renyikun Yuan, Hongwei Gao, Chun Yao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yufang ShenGuangxi University of Chinese Medicine, Traditional Chinese Medicine Zhuang Yao Drug Innovation Drug Engineering Research Center, Nanning, China.
Linyu XiaoCollege of Pharmacy, Guangxi University of Chinese Medicine, Nanning, China.
Lina LiuGuangxi University of Chinese Medicine, Traditional Chinese Medicine Zhuang Yao Drug Innovation Drug Engineering Research Center, Nanning, China.
Lianting LiaoGuangxi University of Chinese Medicine, Traditional Chinese Medicine Zhuang Yao Drug Innovation Drug Engineering Research Center, Nanning, China.
Xianmin ZouGuangxi University of Chinese Medicine, Traditional Chinese Medicine Zhuang Yao Drug Innovation Drug Engineering Research Center, Nanning, China.
Pengfei ShenGuangxi University of Chinese Medicine, Traditional Chinese Medicine Zhuang Yao Drug Innovation Drug Engineering Research Center, Nanning, China.
Jinlong ZhaoCollege of Pharmacy, Guangxi University of Chinese Medicine, Nanning, China.
Renyikun YuanGuangxi University of Chinese Medicine, Traditional Chinese Medicine Zhuang Yao Drug Innovation Drug Engineering Research Center, Nanning, China.
Hongwei GaoGuangxi University of Chinese Medicine, Traditional Chinese Medicine Zhuang Yao Drug Innovation Drug Engineering Research Center, Nanning, China.
Chun YaoGuangxi University of Chinese Medicine, Engineering Research Center in Ministry of Education for Innovative Drugs of Traditional Chinese Medicine and Zhuang Yao Medicine, Nanning, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Abrine, an indole alkaloid, was evaluated for its anti-metastatic activity and mechanism in non-small cell lung cancer (NSCLC) models. Human A549 and H1975 cells were exposed to Abrine, showing no cytotoxicity but marked suppression of TGF-β1-induced migration and invasion by scratch and Transwell assays. Mechanistically, Abrine reversed epithelial-mesenchymal transition (EMT) by upregulating E-cadherin and reducing N-cadherin, vimentin, Snail and Slug, findings corroborated by immunofluorescence. Abrine also diminished phosphorylation of ERK, JNK and p38 while modulating the Nrf2/Keap-1/HO-1 axis. Target engagement was supported by molecular docking, CETSA, DARTS, and MST indicating specific binding and thermal stabilization of ERK.

Indexed as

Carcinoma, Non-Small-Cell LungEpithelial-Mesenchymal TransitionKelch-Like ECH-Associated Protein 1Lung NeoplasmsNF-E2-Related Factor 2A549 CellsAnimalsCell Line, TumorCell MovementHeme Oxygenase-1HumansMAP Kinase Signaling SystemMembrane ProteinsMiceSignal TransductionHeme Oxygenase-1HMOX1 protein, humanKEAP1 protein, humanKelch-Like ECH-Associated Protein 1Membrane ProteinsNFE2L2 protein, humanNF-E2-Related Factor 2Abrineepithelial-mesenchymal transition (EMT)lung metastasis modelMAPKS pathwayNrf2/Keap-1/HO-1 pathway

Identifiers

PMID41972188
PMCPMC13066140

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.